Literature DB >> 9652732

Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases.

T Intragumtornchai1, W Prayoonwiwat, D Swasdikul, N Suwanwela, B Chaimongkol, S Jootar, K Chansung, S Chancharunee, A Leelasiri, Y Yoshida.   

Abstract

To gain more insight into the understanding of myelodysplastic syndromes (MDS) as they occur in Thailand, a retrospective clinicopathologic analysis was conducted in patients (age > 15 years) diagnosed as MDS from January 1992 to December 1996 at the five major medical centers in various geographic regions of the country. The central reviewers independently examined the bone marrow and peripheral blood smears of all the patients and classify the disease according to the French-British-American (FAB) classification. There were a total of 117 eligible patients. The median age of the patients was 56 years (range 16-86). The male:female ratio was 1:1. Thirty-two percent of the patients were younger than 40 years. The frequency of the FAB subtypes was RA/RARS, 54.7; RAEB, 23.1; CMML, 9.4; and RAEB-T, 12.8%. Anemia was the most common symptom presenting in 84.6% of the patients. In the 34 patients in whom the cytogenetics in the bone marrow were analysed, 44.1% revealed abnormalities. Of these, monosomy 7 and trisomy 8 were the most common aberration, each being detected in 26.7% of the patients. Transfusions were the main therapeutic modality in 80% of the patients. Kaplan-Meier analysis revealed a 5 year survival rate of 29% for the whole group with a median survival of 24 months. Twenty-five percent of the patients had progressed to acute myelogenous leukemia (AML) with a median time to disease-progression of 23 months. The median survival for RA/RARS, RAEB, CMML and RAEB-T were 58.4, 19.9, 10.7 and 8.7 months, respectively (P < 0.001). The stepwise Cox regression analysis revealed the percentage of blasts in the bone marrow as the only parameter significantly associated with survival and disease progression. On comparison with data from other countries, the age of Thai patients with MDS is considerably lower than the western population but is comparable to other asian countries. The distribution of the FAB subtypes and the survival of the patients are similar. The major prognostic features, however, lie in the percentage of blasts in the bone marrow rather than the degree of the observed cytopenia.

Entities:  

Mesh:

Year:  1998        PMID: 9652732     DOI: 10.1016/s0145-2126(98)00022-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

Review 1.  Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells.

Authors:  Xiang Li; H Joachim Deeg
Journal:  Exp Hematol       Date:  2013-10-11       Impact factor: 3.084

2.  Treatment of myelodysplastic syndrome with low-dose human granulocyte colony-stimulating factor: a multicenter study.

Authors:  S Chuncharunee; T Intragumtornchai; B Chaimongkol; W Prayoonwiwat; A Leelasiri; A Lekhakula; K Chansung; Y Yoshida
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

Review 3.  What's all the fuss about? facts and figures about bone marrow failure and conditions.

Authors:  Sudipto Mukherjee; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

4.  Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

Authors:  Yoo-Jin Kim; Jun Ho Jang; Jae-Yong Kwak; Je-Hwan Lee; Hyeoung-Joon Kim
Journal:  Blood Res       Date:  2013-06-25

5.  First Cytogenetic Profile of Omani Patients with de novo Myelodysplastic Syndromes: Comparison with data from Asia, Africa, Europe and North and South America.

Authors:  Achandira M Udayakumar; Nagla Fawaz; Anil Pathare; Shakila Asraf; Mohammed Al-Huneini; Khalil Al-Farsi; Salam Al-Kindi; Murtadha Al-Khabouri
Journal:  Sultan Qaboos Univ Med J       Date:  2017-10-10

6.  Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes.

Authors:  Rekha Chaubey; Sudha Sazawal; Rima Dada; Manoranjan Mahapatra; Renu Saxena
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

7.  Immune dysregulation in myelodysplastic syndrome.

Authors:  Chiharu Sugimori; Alan F List; Pearlie K Epling-Burnette
Journal:  Hematol Rep       Date:  2010-01-26

8.  Distinct clinical and experimental characteristics in the patients younger than 60 years old with myelodysplastic syndromes.

Authors:  Xiao Li; Zhi-jian Xiao; Chun-kang Chang; Feng Xu; Ling-yun Wu; Qi He; Ze-feng Xu; Lu-xi Song; Zheng Zhang; Li-yu Zhou; Ji-ying Su; Xi Zhang; Juan Guo
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

9.  A mechanism for 1,4-Benzoquinone-induced genotoxicity.

Authors:  Mi Young Son; Chu-Xia Deng; Jan H Hoeijmarkers; Vivienne I Rebel; Paul Hasty
Journal:  Oncotarget       Date:  2016-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.